title: Cause-specific treatment in patients with high sperm DNA damage resulted in significant DNA improvement.
abstract: Assessment of sperm DNA damage has been suggested as a negative predictor of fertility potential. Multiple pathological factors acting at both the intra-testicular and post-testicular levels may contribute to sperm DNA damage. The relative contribution of each of these factors in an individual with high DNA damage (>30%) is unclear. The management of patients with elevated DNA damage is also challenging. The purpose of our retrospective study was to evaluate the clinical course of patients with sperm DNA damage over 30% and to assess the effect of non-specific (oral antioxidant) and cause-specific treatments on the quality of their sperm DNA. Results of our retrospective study suggest that the evaluated group with high DNA damage was diagnostically heterogeneous and comprised patients with varicoceles, bacteriospermia and idiopathic infertility. A three month course of antioxidant therapy reduced sperm DNA damage in only 30/61 (49%) patients with significant improvement between the initial and post-treatment DNA Fragmentation Index (DFI) results (46.8%+/-14.1 vs. 36.7%+/-16.6, p < .001). The positive effect of antioxidants could be age-dependent, as patients older that 40 years of age showed no improvement after such treatment. The cause-specific treatments showed superior results compared to antioxidants alone. Improvement was observed in 7/9 (78%) of patients after surgical varicocele repair between the initial and post-treatment DFI results (44.7%+/-12.8 vs. 28.4%+/-9.5, p < .03). The majority of the patients 13/14 (93%) with bacteriospermia had improvement in sperm DFI results after antibiotic treatment (50.4%+/-19.1 vs. 38.6%+/-18.7, p < .001).
authors.affiliation: Andrology Laboratory, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. smoskovtsev@mtsinai.on.ca
authors.forename: Sergey I
authors.initials: SI
authors.lastname: Moskovtsev
authors.forename: Irene
authors.initials: I
authors.lastname: Lecker
authors.forename: J Brendan M
authors.initials: JB
authors.lastname: Mullen
authors.forename: Keith
authors.initials: K
authors.lastname: Jarvi
authors.forename: Jennifer
authors.initials: J
authors.lastname: Willis
authors.forename: John
authors.initials: J
authors.lastname: White
authors.forename: Kirk C
authors.initials: KC
authors.lastname: Lo
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use; D004249:DNA Damage; D053938:DNA Fragmentation; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy; D008297:Male; D013094:Spermatozoa / Q000648:ultrastructure*; D014646:Varicocele / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D000975:Antioxidants